Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer

Launched by ASSIUT UNIVERSITY · May 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two different chemotherapy treatment plans for women with stage III and IV ovarian cancer. The main goal is to see if giving 6 cycles of chemotherapy before surgery (called total neoadjuvant chemotherapy) is better than the usual 4 cycles for patients who have shown some improvement or stable disease after initial treatment. The researchers will look at how long patients stay free from cancer-related problems, how safe and tolerable the treatments are, and how quickly the cancer might return after surgery.

To participate in this trial, women must be over 18 years old and recently diagnosed with stage III or IV ovarian cancer, with a response to chemotherapy. However, those with a previous relapse or who cannot tolerate chemotherapy will not be eligible. Participants can expect to undergo 6 cycles of chemotherapy followed by surgery, with ongoing monitoring for side effects and cancer progression. This trial is currently not recruiting, but it aims to provide important insights into the best treatment options for ovarian cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. \> 18 years of age
• • 2. Recently diagnosed with stage III and IV OC
• • 3. Patients eligible for Platinum-based CTH
• • 4. Patients have PR or SD after 3-4 cycles of NACT
• Exclusion Criteria:
• • 1. Relapsed ovarian cancer
• • 2. patients ineligible for Platinum-based CTH
• • 3. Patient not candidate for IDS
• • 4. stage I, II OC
• • 5. Patients progressed after 3 cycles
• • 7-Patients do not tolerate CTH